In an open randomized multicenter comparative study, we evaluated the safety and efficacy of cefepime (CP; 2.0 g given intravenously every 12 h) and ceftazidime (CZ; 2.0 g given intravenously every 8 h) as initial treatment for adult patients with suspected serious bacterial infections. A total of 133 patients entered the study, of whom 114 were evaluable for clinical and microbiological response assessment: 56 received CP and 58 received CZ. About 50%o (30 who received CP and 25 who received CZ) fulfilled the criteria of the sepsis syndrome. The treatment groups were comparable with respect to sex distribution, mean age, underlying diseases, treatment duration, APACHE II score, and type of infection. The most commonly cultured microorganisms were members of the family Enterobacteriaceae, Streptococcus pneumoniae, and Staphylococcus aureus. The causative microorganisms were eradicated from 92% (37 of 40) of patients with a microbiologically documented infection who underwent treatment with CP; they were eradicated from 86% (42 of 49) of patients who received CZ. The responses of only clinically documented infections in the CP group were 90% (27 of 30 patients); in the CZ group they were 87% (26 of 30 patients). When patients fulfilled the criteria of the sepsis syndrome (septic shock excluded), the causative microorganisms were eradicated from 89%o (16 of 18) of CP-treated patients and 86% (12 of 14) of CZ-treated patients. None of these differences was statistically significant. Mortality was the same in both groups (four patients in each group) and was not attributable to the study medication. In conclusion, CP is at least as effective and as safe as CZ as initial antimicrobial therapy for suspected serious bacterial infections in nonneutropenic patients with or without the sepsis syndrome. CP has the additional advantage in that it can be given twice daily, which may lead to a decrease in hospital costs.
Monotherapy with ,-lactam antibiotics (e.g., cephalosporins and carbapenems) has certain advantages over combination antibiotic therapy, since aminoglycosides, with their welldocumented nephro-and ototoxicities, are often part of such combinations, and single-agent therapy is cheaper and at least as effective as combination therapy in nonneutropenic patients (10, 13, 18) . Narrow-spectrum cephalosporins are more active against staphylococci and streptococci than are extendedspectrum cephalosporins. The increased activities of the extended-spectrum cephalosporins against gram-negative microorganisms have been obtained at a cost to their activities against gram-positive microorganisms (la, 3, 5, 15, 28) . Some of the newer members of this class of ,B-lactam antibiotics have achieved clinically relevant activities against Pseudomonas aeruginosa, in addition to their activities against other gramnegative bacteria responsible for many nosocomial infections. Because of this, extended-spectrum cephalosporins have become established as safe and effective when given as empiric monotherapy to nonneutropenic patients with suspected severe bacterial infections (4, 9, 11, 13, 25) .
Cefepime (CP; BMY-28142) is a new broad-spectrum parenteral, so-called "fourth-generation" cephalosporin antibiotic with significant in vitro antimicrobial advantages over other 3-lactam antibiotics (3, 5, 15, 21, 27) . In addition to a broad antimicrobial spectrum, CP has a low binding affinity for the major inducible chromosomally mediated 3-lactamases and can resist hydrolysis by 3-lactamases (5, 14, 21, 23) . Susceptibility testing has indicated that CP is active in vitro against the major bacterial pathogens that cause infections of the lower respiratory tract, urinary tract, skin and soft tissue, and bacteremias, including those caused by gram-negative bacteria such as Pseudomonas spp., Enterobacter spp. and other members of the family Enterobacteriaceae. It also has corresponding potency against gram-positive bacteria such as Staphylococcus aureus and streptococci (1, 3, 5, 15, 21, 23) . The in vitro advantages of CP have been reproduced in several in vivo infection models and have the potential to provide improved antimicrobial therapy, especially against infections caused by bacteria that are resistant to other antibiotics (15, 16, 26 ). In the study described here, the efficacy and safety of CP were compared with those of ceftazidime (CZ), a semisynthetic broad-spectrum 1-lactam antibiotic currently used in the same settings as empiric monotherapy for nonneutropenic adults with suspected serious bacterial infections as well as for neutropenic patients (4, 9, 24 At least two pretreatment blood specimens were obtained for culture from all patients within 72 h before the initiation of therapy. A blood culture set consisted of an aerobic bottle (Septi Check; Roche Diagnostics, Nutley, N.J.) and an anaerobic bottle (cysteine-thioglycolate medium; Oxoid, Basingstoke, United Kingdom); each bottle was filled with 10 ml of blood. All procedures were followed in accordance with the manufacturer's recommendations, and isolates were identified by standard methods. The criterion for the diagnosis of a primary bacteremia was the isolation of a pathogen from the circulating blood, but there could be no other known site of infection. Contamination was defined as isolation of a common (skin) contaminant (e.g., Bacillus spp., coagulase-negative staphylococci, and Corynebacterium spp.) from only one blood culture of a series of at least two or more blood cultures (6) .
Antimicrobial susceptibility testing of both CP and CZ was conducted for all causative pathogens obtained from the site of infection or blood. Susceptibility testing was performed by the MIC method, the disk diffusion measurement method, or by both methods by using the standard methods of the National Committee for Clinical Laboratory Standards (19, 20 b Values in parentheses are number of strains cultured from patients with indwelling urinary catheters. c Early relapse was within 1 to 2 weeks after therapy; late relapse was 4 to 6 weeks after therapy. patients in the CP and CZ groups, respectively). Two of the pathogens cultured from patient specimens at the time of entry into the study in the CZ-treated group were intermediately susceptible to the study drug used (Acinetobacter calcoaceticus MIC, 16 mg/liter; Xanthomonas maltophilia MIC, 16 mg/liter; after 3 days, the MIC for X. maltophilia was 64 mg/liter). All other pathogens (n = 11) were susceptible ( Table 4) . The criteria for the sepsis syndrome (septic shock excluded) were fulfilled in 55 evaluable patients: 30 patients in the CP group and 25 patients in the CZ group (mean APACHE II scores, 19 and 18, respectively). Clinical specimens from 29 of the patients (16 in the CP group, 13 in the CZ group) were culture negative; in two-thirds of these patients in both groups, the infection site was the lower respiratory tract. No significant differences in site of infection, distribution of microorganisms, or response rates were seen between the treatment groups. Of all patients (10 in the CP group; 14 in the CZ group) with primary or secondary bacteremias, 11 patients (6 and 5 patients in the CP and CZ groups, respectively) fulfilled the criteria of the sepsis syndrome. The outcome of clinically documented infections was satisfactory in 87% (14 of 16) of CP-treated patients, while it was 100% (15 of 15) in CZ-treated patients. Eradication of the causative microorganism was achieved in 89% (16 of 18) of the CP-treated patients, whereas it was achieved in 86% (12 of 14) of the CZ-treated patients (Table   5) .
Two patients treated with CP developed a skin rash after therapy. In the CZ group, one patient developed a skin rash after therapy, while another patient had signs of hemolytic anemia. Phlebitis was seen rather frequently: in 28% (19 of 69) of the patients in the CP group and in 17% (11 of 64) of the patients in the CZ group. Eleven patients treated with CP suffered from mild phlebitis (one change of the intravenous site), and seven patients suffered from moderate phlebitis (two or more changes of the intravenous site). One patient had a severe phlebitis which had to be treated with alcohol bandages. Among the patients treated with CZ, seven patients had mild phlebitis and four patients had moderate phlebitis. These differences were not statistically significant, however. DISCUSSION "Fourth-generation" cephalosporins, with CP as an example, have activities similar to those of the extended-spectrum agents, have additional antistaphylococcal and antipseudomonal activities, and are highly P-lactamase stable (11 APACHE II scores, distribution of infection types, underlying diseases, and the use of immunosuppressive therapy. Clinical and microbiological response rates on an intention-to-treat basis did not differ significantly between patients treated with either CP or CZ. Because of early death during therapy, early withdrawal, or the suspicion of the presence of a resistant microorganism, 19 patients were not evaluable. However, no significant differences in the response rates of the remaining 115 evaluable patients were seen. In the 55 patients fulfilling the criteria of the sepsis syndrome (septic shock excluded), no significant differences in response rates were seen. Relapses were all caused by gram-negative microorganisms, but this was never due to resistance of the isolated microorganisms to the drug which was used.
Oster et al. (22) showed that cefepime (1.0 g ql2h) appeared to be well tolerated in humans with LRTIs, UTIs, and skin or soft tissue infections and was effective against a wide range of isolates, including S. aureus and P. aeruginosa. Gentry and Rodriguez-Gomez (7) showed recently that CP (2.0 g ql2h) is well tolerated and appears to be comparable to CZ in the treatment of skin or wound infections and nosocomial UTIs in hospitalized patients. The clinical (98 and 88%, respectively) and microbiological (95 and 96%, respectively) cure rates with CP and CZ reported in those studies were comparable to those seen in our study. Aoun (4, 9, 10, 13, 25) showed comparable clinical (88 to 100%) and microbiological (79 to 95%) response rates. No major adverse effects or side effects from CP, CZ, ceftriaxone, cefotaxime, or imipenem were seen in those studies (4, 9, 10, 13, 25) . Of the three patients treated with CP who developed an early skin rash, one had used an iodine-containing radiocontrast compound the day before. In one of the other patients, skin tests with CP were negative. The high incidence of phlebitis at the participating centers was probably caused by the thorough daily inspection of the intravenous access sites and by the relatively high doses of antibiotics that were given. However, this was also seen in two other recently published multicenter studies (8, 12) . Both drugs, however, appeared to be safe, and no difference between the drugs was found. The fact that CP can be given twice daily may lead to a decrease in hospital costs.
In conclusion, CP (2.0 g ql2h) is as effective and as safe as CZ (2.0 g q8h) as initial antimicrobial therapy for serious bacterial infections in nonneutropenic patients with or without sepsis syndrome.
